Sutton S Scott, Magagnoli Joseph, Hardin James W
Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina.
Health and Demographics, South Carolina Revenue and Fiscal Affairs Office, Columbia, South Carolina.
Pharmacotherapy. 2017 Feb;37(2):204-213. doi: 10.1002/phar.1889. Epub 2017 Feb 3.
To evaluate the odds of achieving viral suppression in human immunodeficiency virus (HIV) patients using antiretroviral therapy as a single-tablet regimen (STR) or multiple-tablet regimen (MTR).
Retrospective cohort study.
South Carolina Medicaid medical and pharmacy paid claims data were obtained from the South Carolina Revenue and Fiscal Affairs Office; laboratory data were obtained from the South Carolina Department of Health and Environmental Control.
A total of 1536 patients who were dispensed a complete STR (477 patients) or MTR (1059 patients) regimen lasting at least 60 days between January 1, 2006, and December 31, 2013.
The analysis examined adherence levels and regimen type on odds of viral load suppression. Regimen adherence levels (90-94%, 85-89%, 80-84%, and less than 80%) were compared with the gold standard adherence for HIV of 95% or greater. Patients were followed from index date until the earliest date of regimen discontinuation, treatment switch, end of study period, last date of eligibility, or death. Differences in outcomes were evaluated by χ , Wilcoxon rank sum statistical tests, and multivariate regression models controlling for covariates. For STR regimens we find that, when compared with 95% or greater adherence, there is no statistical difference in the odds of viral suppression with adherence levels greater than or equal to 80%. However, adherence levels greater than or equal to 95% were associated with a greater odds of viral suppression when compared with less than 80% STR adherence (odds ratio [OR] 2.57, Dunnett 95% confidence interval [CI] 1.04-6.32). For MTR regimens, there was no statistical difference in the odds of viral suppression for the adherence level 90-94% compared with the 95% or greater adherence (OR 3.59, Dunnett 95% CI 0.805-16.043). However, the 95% or greater adherence has greater odds of viral suppression compared with all other MTR adherence levels. In addition, no difference was found in the odds of viral suppression between STR and MTR for all adherence levels.
Compared with 95% or greater adherence, STR regimens achieve viral suppression with adherence levels of 80% or greater, whereas MTR regimens require adherence levels of 90% or greater to achieve viral suppression in South Carolina Medicaid patients with HIV/AIDS.
评估接受抗逆转录病毒疗法单一片剂方案(STR)或多片剂方案(MTR)的人类免疫缺陷病毒(HIV)患者实现病毒抑制的几率。
回顾性队列研究。
南卡罗来纳医疗补助计划的医疗和药房付费索赔数据来自南卡罗来纳州税收与财政事务办公室;实验室数据来自南卡罗来纳州卫生与环境控制部。
2006年1月1日至2013年12月31日期间,共有1536名患者接受了持续至少60天的完整STR方案(477名患者)或MTR方案(1059名患者)。
分析了依从性水平和方案类型对病毒载量抑制几率的影响。将方案依从性水平(90 - 94%、85 - 89%、80 - 84%和低于80%)与HIV的金标准依从性95%及以上进行比较。从索引日期开始对患者进行随访,直至方案停药、治疗转换、研究期结束、资格最后日期或死亡的最早日期。通过χ²检验、Wilcoxon秩和统计检验以及控制协变量的多变量回归模型评估结果差异。对于STR方案,我们发现,与依从性95%及以上相比,依从性大于或等于80%时病毒抑制几率无统计学差异。然而,与STR依从性低于80%相比,依从性大于或等于95%与更高的病毒抑制几率相关(优势比[OR] 2.57,Dunnett 95%置信区间[CI] 1.04 - 6.32)。对于MTR方案,依从性90 - 94%与依从性95%及以上相比,病毒抑制几率无统计学差异(OR 3.59,Dunnett 95% CI 0.805 - 16.043)。然而,与所有其他MTR依从性水平相比,依从性95%及以上具有更高的病毒抑制几率。此外,所有依从性水平下,STR和MTR的病毒抑制几率均未发现差异。
与依从性95%及以上相比,STR方案在依从性达到80%及以上时可实现病毒抑制,而在南卡罗来纳州医疗补助计划的HIV/AIDS患者中,MTR方案需要依从性达到90%及以上才能实现病毒抑制。